Free Trial
→ The Withdrawal You'll Never See on Your Statement (From Bishop Gold Group) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q4 2024 Earnings Results & Report

Innoviva logo
$18.78 -0.30 (-1.57%)
As of 03:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Innoviva reported Q4 2024 earnings on February 26, 2025. The company reported EPS of $0.57, while revenue was $91.81 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Innoviva EPS Results

Actual EPS
$0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

Innoviva Revenue Results

Actual Revenue
$91.81 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Innoviva's Q4 2024 Press ReleasePress Release
(8-K)
Innoviva's Q4 2024 Annual reportAnnual report
(10-K)

Innoviva Q4 2024 Earnings FAQ

Innoviva (NASDAQ:INVA) reported earnings of $0.57 per share for Q4 2024. The report was announced on Wednesday, February 26, 2025.

Innoviva reported revenue of $91.81 million for Q4 2024.

Innoviva Earnings Headlines

Innoviva, Inc. (NASDAQ:INVA) Stock Rated "Moderate Buy" by Wall Street Brokerages
November 9 at 2:59 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31187304
Innoviva (NASDAQ:INVA) Price Target Cut to $34.00 by Analysts at Oppenheimer
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31182522
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
November 11 at 1:00 AM  |  Profits Run (Ad)
Oppenheimer Trims Price Target on Innoviva to $34 From $35, Keeps Outperform Rating
November 5, 2026  |  marketscreener.comM
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
November 4, 2026  |  marketscreener.comM
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
November 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261104246173/en/innoviva-reports-third-quarter-2026-financial-results-highlights-recent-company-progress/
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA) is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK.

Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions. Its portfolio includes products such as Xenleta and Xacduro for certain bacterial infections, Xerava for complicated intra-abdominal infections, and Giapreza for dangerously low blood pressure in adults with septic or other distributive shock.

The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2015, following the separation of Theravance Biopharma. Innoviva’s products and royalty arrangements give it a presence in markets beyond the United States, though the geographic reach varies by product and commercial partner.

View Innoviva Profile
Earnings Tools